tradmap

NTLA Intellia Therapeutics, Inc.

$15.65 +2.25%

Healthcare · In Vitro & In Vivo Diagnostic Substances

Intellia Therapeutics, Inc. (NTLA) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $2.2 billion. Shares last traded at $15.65, 12.1% below their 52-week high. Over the past year the stock is up 227.2%. Net profit margin is -609.9%, below the peer median of -3.8%. Revenue grew 16.9% year over year.

Market Cap
$2.2B
Shares Out
139.7M
EPS (TTM)
$-6.98
P/E Ratio
P/S Ratio
32.32
P/B Ratio
3.52
Dividend / Share
Dividend Yield
52-Week High
$17.82
52-Week Low
$4.44
Volume
274,461
Avg Vol (3m)
311,583.286

Performance

1W
+26.05%
1M
+31.33%
3M
+19.05%
6M
+71.66%
YTD
+69.52%
1Y
+227.17%

Daily candles · volume · SMA(20)/SMA(50) · split-adjusted · Databento EQUS.MINI.

Technicals

RSI (14)
61.43
SMA (50)
$13.80
SMA (200)
$11.68
Price vs SMA50
+13.44%
Price vs SMA200
+34.06%
ATR (14)
$1.32

Financials

Revenue
$68M
Net Income
$-413M
Gross Margin
Operating Margin
-651.7%
Net Margin
-609.9%
Return on Equity
-66.5%
Return on Assets
-54.4%
Current Ratio
6.10
Debt / Equity
0.22
Revenue Growth (YoY)
+16.9%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.81 2026-05-11
FY 2025 $-3.81 2026-02-26
Q3 2025 $-2.99 2025-11-06
Q2 2025 $-2.08 2025-08-07
Q1 2026 $-1.10 2026-05-11
FY 2025 $-5.25 2026-02-26

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

NTLA vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap.

P/S vs peers
32.32 / 4.39 med
+637% premium
Net margin vs peers
-609.9% / -3.8% med
below median
1–14 of 14
IDXXIdexx Laboratories$44.3B41.8410.3024.6%+2.91%
LNTHLantheus Holdings, Inc.$6.8B28.974.3915.2%+0.67%
CLDXCelldex Therapeutics, Inc.$2.5B-9.84-1.47%
NTLAIntellia Therapeutics, Inc.$2.2B-5.30+2.25%
NEOGNeogen Corp$2.0B-1.85+4.14%
QDELQuidelortho Corp$932M+4.27%
ACHVAchieve Life Sciences, Inc.$496M-9.07-9.72%
MYGNMyriad Genetics Inc$429M-1.170.52-44.4%+3.65%
TKNOAlpha Teknova, Inc.$282M-16.326.95-42.6%+6.38%
IMDXInsight Molecular Diagnostics Inc.$176M-3510.5043.48-1.2%+2.25%
ICCCIMMUCELL CORP /DE/$86M-82.253.09-3.8%+0.53%
QCLSQ/C TECHNOLOGIES, INC.$32M-2.72+4.28%
VNRXVOLITIONRX LTD$12M-0.52+6.14%
CDIOCardio Diagnostics Holdings, Inc.$6M+2.53%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.